Sanofi

Innovation isn’t just about design—it’s about pushing boundaries in every field. ✨ From Milan to the world–where bold ideas shape the future. 👀 #MDW2025 #SanofiTour Atelier blam

At Sanofi, we are working every day deep in the nexus between health and the environment. More than 70% of our portfolio and pipeline address diseases that can be made worse by environmental change. We’re also conducting studies to identify methods for reducing the environmental impact of patient care. One approach is to promote prevention through immunization, which helps to decarbonize the healthcare system. Read more on how we’re making a difference: http://spkl.io/6041fa939

At Milan Design Week, we celebrate the power of bold ideas and cutting-edge innovation–whether in healthcare, sport, or design. Shaping the future means embracing creativity and daring to rethink what’s possible. ✨ We believe that innovation thrives where disciplines intersect. Just as design transforms spaces, scientific breakthroughs redefine possibilities in health. This shared vision drives us forward. Join us in Milan as we celebrate creativity without limits! 🐎 🇮🇹 #MDW2025 #SanofiTour Atelier blam

Phase 3 data results for our investigational #MultipleSclerosis treatment were published in The New England Journal of Medicine and presented at the American Academy of Neurology’s Annual Meeting 2025. These data represent our commitment to the #MultipleSclerosis community, where there remains a critical unmet need to address disability accumulation. Our mission is to help those living with MS live for the moment, not for the disease. #AANAM Read our press release ➡️ http://spkl.io/6043faOUZ

Almost half of the world’s population lives in an area sensitive to climate change, putting their health at risk. We’re tackling the impact of environmental change on health and #healthcare. Join us in celebrating #WorldHealthDay by learning about how we’re embedding sustainability across our business to protect people and the planet: http://spkl.io/6042fvC2M #Sustainability

When we develop a new medicine, we give patients a voice in our R&D process. This creates a continuous feedback loop which ensures our innovations truly address their needs. Hear from our Global Head of Translational Medicine, Karin Wåhlander, about the vital connection between lab and real life: http://spkl.io/6047fvMwt #WeNeverSettle #TranslationalMedicine

The FDA has granted Orphan Drug Designation to our investigational Bruton’s tyrosine kinase (BTK) inhibitor for two rare, immune-mediated indications that have no currently approved medicines. Read the full press release: http://spkl.io/6046fvkjn

Turning the breakthroughs of research into real-world advances for patients is about more than invention. Success hinges on R&D and manufacturing working side by side to bring science to life. Read more from Franck Leroux and Shawn D. Walker about how R&D and M&S work together to deliver life-changing medicines: http://spkl.io/6043fvRXb #WeNeverSettle #DigitalTransformation

#NEWS: The FDA approved our treatment for adult and pediatric patients (12+) with hemophilia A or B with or without inhibitors. This milestone underscores our commitment to pushing the boundaries of innovation and improving care for people with #RareBloodDisorders. Read our press release: http://spkl.io/6042fQY2w

Our medicine is now approved in Japan by the Ministry of Health, Labor and Welfare for adults with uncontrolled chronic obstructive pulmonary disease (#COPD). This first-of-its-kind treatment option is an important step toward improving care for people with this progressive respiratory disease in Japan. Read more about the news: http://spkl.io/6040fQjqp CC: Regeneron